Dr. Pedro Rosa-Neto

  1. Ossenkoppele, R, Coomans, EM, Apostolova, LG, Baker, SL, Barthel, H, Beach, TG et al.. Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex. Nat Neurosci. 2025; :. doi: 10.1038/s41593-025-02000-6. PubMed PMID:40670684 .
  2. Rohden, F, Ferreira, PCL, Bellaver, B, Ferrari-Souza, JP, Aguzzoli, CS, Soares, C et al.. Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease. Nat Commun. 2025;16 (1):5653. doi: 10.1038/s41467-025-60806-1. PubMed PMID:40593718 PubMed Central PMC12215965.
  3. Moscoso, A, Heeman, F, Raghavan, S, Costoya-Sánchez, A, van Essen, M, Mainta, I et al.. Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity. JAMA. 2025;334 (3):229-242. doi: 10.1001/jama.2025.7817. PubMed PMID:40522652 .
  4. Abbas, S, Ferreira, PCL, Bellaver, B, Povala, G, Rohden, F, Aguzzoli, CS et al.. Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease. J Prev Alzheimers Dis. 2025;12 (7):100205. doi: 10.1016/j.tjpad.2025.100205. PubMed PMID:40473528 .
  5. Chen, CD, Franklin, EE, Li, Y, Joseph-Mathurin, N, Burns, AL, Hobbs, DA et al.. Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta Neuropathol. 2025;149 (1):57. doi: 10.1007/s00401-025-02890-7. PubMed PMID:40459787 PubMed Central PMC12133910.
  6. Planche, V, Mansencal, B, Fonov, V, Manjon, JV, Tourdias, T, Bouzigues, A et al.. Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan. Brain. 2025; :. doi: 10.1093/brain/awaf195. PubMed PMID:40424598 .
  7. Hosseini, E, Hosseini, SA, Servaes, S, Hall, B, Rosa-Neto, P, Moradi, AR et al.. Transforming 3D MRI to 2D Feature Maps Using Pre-Trained Models for Diagnosis of Attention Deficit Hyperactivity Disorder. Tomography. 2025;11 (5):. doi: 10.3390/tomography11050056. PubMed PMID:40423258 PubMed Central PMC12115681.
  8. Bellaver, B, Povala, G, Ferreira, PCL, Bauer-Negrini, G, Lussier, FZ, Leffa, DT et al.. Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer’s disease. Alzheimers Dement. 2025;21 (5):e70209. doi: 10.1002/alz.70209. PubMed PMID:40346617 PubMed Central PMC12064411.
  9. Gauthier, S, Therriault, J, Rosa-Neto, P. Cholinergic therapy in Alzheimer disease. Handb Clin Neurol. 2025;211 :155-159. doi: 10.1016/B978-0-443-19088-9.00015-9. PubMed PMID:40340059 .
  10. Weiner, S, Sauer, M, Montoliu-Gaya, L, Benedet, AL, Ashton, NJ, Gonzalez-Ortiz, F et al.. Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’. Mol Neurodegener. 2025;20 (1):52. doi: 10.1186/s13024-025-00841-0. PubMed PMID:40329321 PubMed Central PMC12057231.
  11. Pola, I, Ashton, NJ, Antônio De Bastiani, M, Brum, WS, Rahmouni, N, Tan, K et al.. Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer’s disease. Alzheimers Dement. 2025;21 (4):e70171. doi: 10.1002/alz.70171. PubMed PMID:40289873 PubMed Central PMC12035552.
  12. Bezgin, G, Pascoal, TA, Therriault, J, Lussier, FZ, Servaes, S, Kang, MS et al.. Tau profiling across Alzheimer’s disease staging reveals vulnerability to disease pathophysiology. Eur J Nucl Med Mol Imaging. 2025; :. doi: 10.1007/s00259-025-07257-4. PubMed PMID:40274672 .
  13. Borelli, WV, Ferreira, PCL, Brum, WS, Ferrari-Souza, JP, Carello-Collar, G, Holz, M et al.. Diagnostic performance of Alzheimer’s disease blood biomarkers in a Brazilian cohort. medRxiv. 2025; :. doi: 10.1101/2025.02.23.24319116. PubMed PMID:40271009 PubMed Central PMC12016014.
  14. Mirza, SS, Pasternak, M, Paterson, AD, Rogaeva, E, Tartaglia, MC, Mitchell, SB et al.. Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study. Brain. 2025; :. doi: 10.1093/brain/awaf019. PubMed PMID:40260680 .
  15. Lantero-Rodriguez, J, Montoliu-Gaya, L, Benedet, AL, Vrillon, A, Dumurgier, J, Cognat, E et al.. Correction: CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease. Acta Neuropathol. 2025;149 (1):34. doi: 10.1007/s00401-025-02877-4. PubMed PMID:40257474 PubMed Central PMC12011925.
  16. Iturria-Medina, Y, Poole, VN, Zammit, AR, Yu, L, Tasaki, S, Hong, JH et al.. Translating the Post-Mortem Brain Multi-Omics Molecular Taxonomy of Alzheimer’s Dementia to Living Humans. bioRxiv. 2025; :. doi: 10.1101/2025.03.20.644323. PubMed PMID:40196602 PubMed Central PMC11974700.
  17. Leffa, D, Povala, G, Ferreira, P, Ferrari-Souza, JP, Bauer-Negrini, G, Rodrigues, M et al.. In vivo-measured Lewy body pathology is associated with neuropsychiatric symptoms across the Alzheimer’s disease continuum. Res Sq. 2025; :. doi: 10.21203/rs.3.rs-6270682/v1. PubMed PMID:40196010 PubMed Central PMC11975041.
  18. Aliaga, A, Therriault, J, Quispialaya, K, Aliaga, A, Kunach, P, Macedo, AC et al.. Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue. EJNMMI Res. 2025;15 (1):30. doi: 10.1186/s13550-025-01216-8. PubMed PMID:40167827 PubMed Central PMC11961831.
  19. Ossenkoppele, R, Salvadó, G, Janelidze, S, Pichet Binette, A, Bali, D, Karlsson, L et al.. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat Aging. 2025;5 (5):883-896. doi: 10.1038/s43587-025-00835-z. PubMed PMID:40155777 PubMed Central PMC12092243.
  20. Bateman, RJ, Li, Y, McDade, EM, Llibre-Guerra, JJ, Clifford, DB, Atri, A et al.. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 2025;24 (4):316-330. doi: 10.1016/S1474-4422(25)00024-9. PubMed PMID:40120616 PubMed Central PMC12042767.
  21. Lantero-Rodriguez, J, Montoliu-Gaya, L, Ashton, NJ, Pola, I, Therriault, J, Rahmouni, N et al.. Biofluid-based staging of Alzheimer’s disease. Acta Neuropathol. 2025;149 (1):27. doi: 10.1007/s00401-025-02863-w. PubMed PMID:40095069PubMed Central PMC11913990.
  22. Tremblay, C, Rahayel, S, Pastor-Bernier, A, St-Onge, F, Vo, A, Rheault, F et al.. Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer’s disease. Brain Commun. 2025;7 (2):fcaf099. doi: 10.1093/braincomms/fcaf099. PubMed PMID:40092368 PubMed Central PMC11906971.
  23. Hosseini, SA, Hajianfar, G, Hall, B, Servaes, S, Rosa-Neto, P, Ghafarian, P et al.. Robust vs. Non-robust radiomic features: the quest for optimal machine learning models using phantom and clinical studies. Cancer Imaging. 2025;25 (1):33. doi: 10.1186/s40644-025-00857-1. PubMed PMID:40075547 PubMed Central PMC11905451.
  24. Alpaugh, M, Lantero-Rodriguez, J, Benedet, AL, Manseau, U, Boutin, M, Maiuri, M et al.. Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity. J Neurol. 2025;272 (3):254. doi: 10.1007/s00415-025-12966-9. PubMed PMID:40047995 PubMed Central PMC11885373.
  25. Yakoub, Y, Gonzalez-Ortiz, F, Ashton, NJ, Déry, C, Strikwerda-Brown, C, St-Onge, F et al.. Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window. Alzheimers Dement. 2025;21 (2):e14537. doi: 10.1002/alz.14537. PubMed PMID:40008832 PubMed Central PMC11863240.
  26. Leffa, DT, Povala, G, Bellaver, B, Ferrari-Souza, JP, Ferreira, PCL, Lussier, FZ et al.. Impact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer’s disease. Alzheimers Dement. 2025;21 (2):e70003. doi: 10.1002/alz.70003. PubMed PMID:39998851 PubMed Central PMC11853731.
  27. Milella, MS, Minuzzi, L, Benkelfat, C, Soucy, JP, Kirlow, A, Schirrmacher, E et al.. Quantification of [11C]ABP688 Binding to mGluR5 in Human Brain using Cerebellum as Reference Region: Biological Interpretation and Limitations. Curr Neuropharmacol. 2025;23 (9):1081-1094. doi: 10.2174/1570159X23666250127161855. PubMed PMID:39976038 PubMed Central PMC12272086.
  28. Bateman, RJ, Li, Y, McDade, EM, Llibre-Guerra, JJ, Clifford, DB, Atri, A et al.. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial. medRxiv. 2025; :. doi: 10.1101/2024.10.29.24316289. PubMed PMID:39974075 PubMed Central PMC11838922.
  29. Arslan, B, Brum, WS, Pola, I, Therriault, J, Rahmouni, N, Stevenson, J et al.. The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity. Alzheimers Res Ther. 2025;17 (1):48. doi: 10.1186/s13195-025-01692-z. PubMed PMID:39972340 PubMed Central PMC11837363.
  30. Yun, J, Shin, D, Lee, EH, Kim, JP, Ham, H, Gu, Y et al.. Temporal Dynamics and Biological Variability of Alzheimer Biomarkers. JAMA Neurol. 2025;82 (4):384-96. doi: 10.1001/jamaneurol.2024.5263. PubMed PMID:39960728 PubMed Central PMC11833660.
  31. Islam, T, Hill, E, Abrahamson, EE, Servaes, S, Smirnov, DS, Zeng, X et al.. Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease. Nat Med. 2025;31 (2):574-588. doi: 10.1038/s41591-024-03400-0. PubMed PMID:39930142 PubMed Central PMC11835754.
  32. Llibre-Guerra, JJ, Fernandez, MV, Joseph-Mathurin, N, Bian, S, Carter, K, Li, Y et al.. Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia. Nat Med. 2025;31 (4):1267-1275. doi: 10.1038/s41591-025-03494-0. PubMed PMID:39930140 PubMed Central PMC12024232.
  33. Sogorb-Esteve, A, Weiner, S, Simrén, J, Swift, IJ, Bocchetta, M, Todd, EG et al.. Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes. Sci Transl Med. 2025;17 (784):eadm9654. doi: 10.1126/scitranslmed.adm9654. PubMed PMID:39908349 .
  34. Liu, H, Marsh, TW, Shi, X, Renton, AE, Bowling, KM, Ziegemeier, E et al.. The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset. Brain. 2025;148 (7):2429-2440. doi: 10.1093/brain/awaf038. PubMed PMID:39903689 PubMed Central PMC12233549.
  35. Smith, EE, Phillips, NA, Feldman, HH, Borrie, M, Ganesh, A, Henri-Bhargava, A et al.. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research. J Prev Alzheimers Dis. 2025;12 (3):100068. doi: 10.1016/j.tjpad.2025.100068. PubMed PMID:39893139 PubMed Central PMC12184013.
  36. Da Ros, LU, Borelli, WV, Aguzzoli, CS, De Bastiani, MA, Schilling, LP, Santamaria-Garcia, H et al.. Social and health disparities associated with healthy brain ageing in Brazil and in other Latin American countries. Lancet Glob Health. 2025;13 (2):e277-e284. doi: 10.1016/S2214-109X(24)00451-0. PubMed PMID:39890228 PubMed Central PMC12035733.
  37. Fernández Arias, J, Brum, WS, Salvadó, G, Therriault, J, Servaes, S, Wang, YT et al.. Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum. Brain. 2025;148 (7):2384-2399. doi: 10.1093/brain/awaf033. PubMed PMID:39879633 .
  38. Wang, YT, Ashton, NJ, Therriault, J, Benedet, AL, Macedo, AC, Pola, I et al.. Identify biological Alzheimer’s disease using a novel nucleic acid-linked protein immunoassay. Brain Commun. 2025;7 (1):fcaf004. doi: 10.1093/braincomms/fcaf004. PubMed PMID:39845736 PubMed Central PMC11753389.
  39. Hosseini, SA, Servaes, S, Hall, B, Bhaduri, S, Rajan, A, Rosa-Neto, P et al.. Quantitative Physiologic MRI Combined with Feature Engineering for Developing Machine Learning-Based Prediction Models to Distinguish Glioblastomas from Single Brain Metastases. Diagnostics (Basel). 2024;15 (1):. doi: 10.3390/diagnostics15010038. PubMed PMID:39795566 PubMed Central PMC11720653.
  40. Quispialaya, KM, Therriault, J, Aliaga, A, Benedet, AL, Ashton, NJ, Karikari, T et al.. Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia. Neurology. 2025;104 (2):e210211. doi: 10.1212/WNL.0000000000210211. PubMed PMID:39715476 PubMed Central PMC11666273.
  41. Chertkow, H, Phillips, N, Rockwood, K, Anderson, N, Andrew, MK, Bartha, R et al.. Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA). J Alzheimers Dis. 2024;102 (3):535-561. doi: 10.1177/13872877241290990. PubMed PMID:39636028 .
  42. Aumont, E, Bedard, MA, Bussy, A, Arias, JF, Tissot, C, Hall, BJ et al.. Hippocampal atrophy over two years in relation to tau, amyloid-β and memory in older adults. Neurobiol Aging. 2025;146 :48-57. doi: 10.1016/j.neurobiolaging.2024.11.007. PubMed PMID:39631245 .
  43. Hofmann, A, Häsler, LM, Lambert, M, Kaeser, SA, Gräber-Sultan, S, Obermüller, U et al.. Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease. Nat Commun. 2024;15 (1):9982. doi: 10.1038/s41467-024-52937-8. PubMed PMID:39557867 PubMed Central PMC11574007.
  44. Therriault, J, Janelidze, S, Benedet, AL, Ashton, NJ, Arranz Martínez, J, Gonzalez-Escalante, A et al.. Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability. Nat Aging. 2024;4 (11):1529-1537. doi: 10.1038/s43587-024-00731-y. PubMed PMID:39533113 PubMed Central PMC11564087.
  45. Woo, MS, Therriault, J, Jonaitis, EM, Wilson, R, Langhough, RE, Rahmouni, N et al.. Identification of late-stage tau accumulation using plasma phospho-tau217. EBioMedicine. 2024;109 :105413. doi: 10.1016/j.ebiom.2024.105413. PubMed PMID:39500009 PubMed Central PMC11570195.
  46. Duchesne, S, Collins, DL, Barlow, L, Bartha, R, Black, S, Chertkow, H et al.. Recommendations on Imaging in the Context of Alzheimer’s Disease-Modifying Therapies from the CCNA Imaging Workgroup. Can J Neurol Sci. 2024; :1-9. doi: 10.1017/cjn.2024.338. PubMed PMID:39494933 .
  47. Aliaga, A, Therriault, J, Quispialaya, KM, Aliaga, A, Hopewell, R, Rahmouni, N et al.. Comparison Between Brain and Cerebellar Autoradiography Using [18F]Flortaucipir, [18F]MK6240, and [18F]PI2620 in Postmortem Human Brain Tissue. J Nucl Med. 2025;66 (1):123-129. doi: 10.2967/jnumed.124.267539. PubMed PMID:39477493 .
  48. Quispialaya, KM, Therriault, J, Aliaga, A, Tissot, C, Servaes, S, Rahmouni, N et al.. Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease. Eur J Neurol. 2024;31 (12):e16255. doi: 10.1111/ene.16255. PubMed PMID:39447157 PubMed Central PMC11555153.
  49. Pascoal, TA, Aguzzoli, CS, Lussier, FZ, Crivelli, L, Suemoto, CK, Fortea, J et al.. Insights into the use of biomarkers in clinical trials in Alzheimer’s disease. EBioMedicine. 2024;108 :105322. doi: 10.1016/j.ebiom.2024.105322. PubMed PMID:39366844 PubMed Central PMC11663755.
  50. Kunach, P, Vaquer-Alicea, J, Smith, MS, Monistrol, J, Hopewell, R, Moquin, L et al.. Cryo-EM structure of Alzheimer’s disease tau filaments with PET ligand MK-6240. Nat Commun. 2024;15 (1):8497. doi: 10.1038/s41467-024-52265-x. PubMed PMID:39353896 PubMed Central PMC11445244.
  51. Shen, Y, Timsina, J, Heo, G, Beric, A, Ali, M, Wang, C et al.. CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease. Cell. 2024;187 (22):6309-6326.e15. doi: 10.1016/j.cell.2024.08.049. PubMed PMID:39332414PubMed Central PMC11531390.
  52. Macedo, AC, Therriault, J, Tissot, C, Aumont, É, Servaes, S, Rahmouni, N et al.. Modeling the progression of neuropsychiatric symptoms in Alzheimer’s disease with PET-based Braak staging. Neurobiol Aging. 2024;144 :127-137. doi: 10.1016/j.neurobiolaging.2024.09.009. PubMed PMID:39326302 .
  53. Wiesman, AI, Madge, V, Fon, EA, Dagher, A, Collins, DL, Baillet, S et al.. Associations between neuromelanin depletion and cortical rhythmic activity in Parkinson’s disease. Brain. 2025;148 (3):875-885. doi: 10.1093/brain/awae295. PubMed PMID:39282945 PubMed Central PMC11884654.
  54. Hosseini, SA, Hajianfar, G, Ghaffarian, P, Seyfi, M, Hosseini, E, Aval, AH et al.. PET radiomics-based lymphovascular invasion prediction in lung cancer using multiple segmentation and multi-machine learning algorithms. Phys Eng Sci Med. 2024;47 (4):1613-1625. doi: 10.1007/s13246-024-01475-0. PubMed PMID:39225775 PubMed Central PMC11666702.
  55. Pascoal, T, Rohden, F, Ferreira, P, Bellaver, B, Ferrari-Souza, JP, Aguzzoli, C et al.. Glial reactivity is linked to synaptic dysfunction across the aging and Alzheimer’s disease spectrum. Res Sq. 2024; :. doi: 10.21203/rs.3.rs-4782732/v1. PubMed PMID:39184102 PubMed Central PMC11343173.
  56. Bieger, A, Brum, WS, Borelli, WV, Therriault, J, De Bastiani, MA, Moreira, AG et al.. Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research. Neurology. 2024;103 (5):e209753. doi: 10.1212/WNL.0000000000209753. PubMed PMID:39167736 PubMed Central PMC11338500.
  57. Daniels, AJ, McDade, E, Llibre-Guerra, JJ, Xiong, C, Perrin, RJ, Ibanez, L et al.. 15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN. medRxiv. 2024; :. doi: 10.1101/2024.08.08.24311689. PubMed PMID:39148846 PubMed Central PMC11326320.
  58. Povala, G, De Bastiani, MA, Bellaver, B, Ferreira, PCL, Ferrari-Souza, JP, Lussier, FZ et al.. Omics-derived biological modules reflect metabolic brain changes in Alzheimer’s disease. Alzheimers Dement. 2024;20 (10):6709-6721. doi: 10.1002/alz.14095. PubMed PMID:39140361 PubMed Central PMC11485394.
  59. Serpente, M, Fenoglio, C, Arcaro, M, Carandini, T, Sacchi, L, Pintus, M et al.. Long Non-Coding RNA Profile in Genetic Symptomatic and Presymptomatic Frontotemporal Dementia: A GENFI Study. J Alzheimers Dis. 2024;100 (s1):S187-S196. doi: 10.3233/JAD-240557. PubMed PMID:39121124 PubMed Central PMC11380264.
  60. Schultz, SA, Liu, L, Schultz, AP, Fitzpatrick, CD, Levin, R, Bellier, JP et al.. γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2024;23 (9):913-924. doi: 10.1016/S1474-4422(24)00236-9. PubMed PMID:39074479 PubMed Central PMC11822357.
  61. Leuzy, A, Raket, LL, Villemagne, VL, Klein, G, Tonietto, M, Olafson, E et al.. Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model. Alzheimers Dement. 2024;20 (9):5833-5848. doi: 10.1002/alz.13908. PubMed PMID:39041435 PubMed Central PMC11497758.
  62. Wang, YT, Therriault, J, Tissot, C, Servaes, S, Rahmouni, N, Macedo, AC et al.. Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts. Alzheimers Res Ther. 2024;16 (1):162. doi: 10.1186/s13195-024-01509-5. PubMed PMID:39034389 PubMed Central PMC11265084.
  63. Premi, E, Diano, M, Mattioli, I, Altomare, D, Cantoni, V, Bocchetta, M et al.. Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study. Brain Commun. 2024;6 (4):fcae185. doi: 10.1093/braincomms/fcae185. PubMed PMID:39015769 PubMed Central PMC11249959.
  64. Sanchez-Rodriguez, LM, Khan, AF, Adewale, Q, Bezgin, G, Therriault, J, Fernandez-Arias, J et al.. In-vivo neuronal dysfunction by Aβ and tau overlaps with brain-wide inflammatory mechanisms in Alzheimer’s disease. Front Aging Neurosci. 2024;16 :1383163. doi: 10.3389/fnagi.2024.1383163. PubMed PMID:38966801 PubMed Central PMC11223503.
  65. Ossenkoppele, R, Salvadó, G, Janelidze, S, Binette, AP, Bali, D, Karlsson, L et al.. Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology. medRxiv. 2024; :. doi: 10.1101/2024.06.12.24308824. PubMed PMID:38947004 PubMed Central PMC11213114.
  66. Poirier, A, Picard, C, Labonté, A, Aubry, I, Auld, D, Zetterberg, H et al.. PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer’s disease. Sci Rep. 2024;14 (1):14718. doi: 10.1038/s41598-024-65104-2. PubMed PMID:38926456 PubMed Central PMC11208446.
  67. da Silva Castanheira, J, Wiesman, AI, Hansen, JY, Misic, B, Baillet, S, PREVENT-AD Research Group et al.. The neurophysiological brain-fingerprint of Parkinson’s disease. EBioMedicine. 2024;105 :105201. doi: 10.1016/j.ebiom.2024.105201. PubMed PMID:38908100 PubMed Central PMC11253223.
  68. Ottoy, J, Kang, MS, Tan, JXM, Boone, L, Vos de Wael, R, Park, BY et al.. Tau follows principal axes of functional and structural brain organization in Alzheimer’s disease. Nat Commun. 2024;15 (1):5031. doi: 10.1038/s41467-024-49300-2. PubMed PMID:38866759 PubMed Central PMC11169286.
  69. Wearn, A, Tremblay, SA, Tardif, CL, Leppert, IR, Gauthier, CJ, Baracchini, G et al.. Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status. Nat Commun. 2024;15 (1):4706. doi: 10.1038/s41467-024-48490-z. PubMed PMID:38830849 PubMed Central PMC11148077.
  70. Wang, YT, Ashton, NJ, Servaes, S, Nilsson, J, Woo, MS, Pascoal, TA et al.. The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease. Transl Neurodegener. 2024;13 (1):27. doi: 10.1186/s40035-024-00420-1. PubMed PMID:38802928 PubMed Central PMC11131272.
  71. Yakoub, Y, Gonzalez-Ortiz, F, Ashton, NJ, Déry, C, Strikwerda-Brown, C, St-Onge, F et al.. Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults. medRxiv. 2024; :. doi: 10.1101/2024.05.09.24307120. PubMed PMID:38766113 PubMed Central PMC11100946.
  72. Sanchez-Rodriguez, LM, Bezgin, G, Carbonell, F, Therriault, J, Fernandez-Arias, J, Servaes, S et al.. Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer’s disease. Commun Biol. 2024;7 (1):528. doi: 10.1038/s42003-024-06217-2. PubMed PMID:38704445 PubMed Central PMC11069569.
  73. Kroll, T, Miranda, A, Drechsel, A, Beer, S, Lang, M, Drzezga, A et al.. Dynamic neuroreceptor positron emission tomography in non-anesthetized rats using point source based motion correction: A feasibility study with [11C]ABP688. J Cereb Blood Flow Metab. 2024;44 (10):1852-1866. doi: 10.1177/0271678X241239133. PubMed PMID:38684219PubMed Central PMC11504418.
  74. Wagemann, O, Liu, H, Wang, G, Shi, X, Bittner, T, Scelsi, MA et al.. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024;81 (6):582-593. doi: 10.1001/jamaneurol.2024.0991. PubMed PMID:38683602 PubMed Central PMC11059071.
  75. Butler, T, Wang, X, Chiang, G, Xi, K, Niogi, S, Glodzik, L et al.. Reduction in Constitutively Activated Auditory Brainstem Microglia in Aging and Alzheimer’s Disease. J Alzheimers Dis. 2024;99 (1):307-319. doi: 10.3233/JAD-231312. PubMed PMID:38669537 PubMed Central PMC11091576.
  76. Wisch, JK, McKay, NS, Boerwinkle, AH, Kennedy, J, Flores, S, Handen, BL et al.. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 2024;23 (5):500-510. doi: 10.1016/S1474-4422(24)00084-X. PubMed PMID:38631766 PubMed Central PMC11209765.
  77. Walker, CS, Li, L, Baracchini, G, Tremblay-Mercier, J, Spreng, RN, PREVENT-AD Research Group et al.. Neurobehavioral Mechanisms Influencing the Association Between Generativity, the Desire to Promote Well-Being of Younger Generations, and Purpose in Life in Older Adults at Risk for Alzheimer’s Disease. J Gerontol B Psychol Sci Soc Sci. 2024;79 (6):. doi: 10.1093/geronb/gbae060. PubMed PMID:38623965 PubMed Central PMC11138215.
  78. Pasternak, M, Mirza, SS, Luciw, N, Mutsaerts, HJMM, Petr, J, Thomas, D et al.. [Not Available]. Alzheimers Dement. 2024;20 (5):3525-3542. doi: 10.1002/alz.13750. PubMed PMID:38623902 PubMed Central PMC11095434.
  79. Samra, K, Peakman, G, MacDougall, AM, Bouzigues, A, Greaves, CV, Convery, RS et al.. Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia. Alzheimers Dement (Amst). 2024;16 (2):e12571. doi: 10.1002/dad2.12571. PubMed PMID:38623386 PubMed Central PMC11016817.
  80. Dauar, MT, Picard, C, Labonté, A, Breitner, J, Rosa-Neto, P, Villeneuve, S et al.. Contactin 5 and Apolipoproteins Interplay in Alzheimer’s Disease. J Alzheimers Dis. 2024;98 (4):1361-1375. doi: 10.3233/JAD-231003. PubMed PMID:38578887 .
  81. Hosseini, SA, Shiri, I, Ghaffarian, P, Hajianfar, G, Avval, AH, Seyfi, M et al.. The effect of harmonization on the variability of PET radiomic features extracted using various segmentation methods. Ann Nucl Med. 2024;38 (7):493-507. doi: 10.1007/s12149-024-01923-7. PubMed PMID:38575814 PubMed Central PMC11217131.
  82. Doering, S, McCullough, A, Gordon, BA, Chen, CD, McKay, N, Hobbs, D et al.. Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging. EBioMedicine. 2024;103 :105080. doi: 10.1016/j.ebiom.2024.105080. PubMed PMID:38552342 PubMed Central PMC10995809.
  83. Baril, AA, Picard, C, Labonté, A, Sanchez, E, Duclos, C, Mohammediyan, B et al.. Longer sleep duration and neuroinflammation in at-risk elderly with a parental history of Alzheimer’s disease. Sleep. 2024;47 (6):. doi: 10.1093/sleep/zsae081. PubMed PMID:38526098 PubMed Central PMC11168764.
  84. Brum, WS, Cullen, NC, Therriault, J, Janelidze, S, Rahmouni, N, Stevenson, J et al.. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat Commun. 2024;15 (1):2311. doi: 10.1038/s41467-024-46603-2. PubMed PMID:38486040 PubMed Central PMC10940585.
  85. Macedo, AC, Therriault, J, Tissot, C, Fernandez-Arias, J, Ferreira, PCL, Vitali, P et al.. Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging. Brain Commun. 2024;6 (2):fcae043. doi: 10.1093/braincomms/fcae043. PubMed PMID:38482373 PubMed Central PMC10935644.
  86. Therriault, J, Ashton, NJ, Pola, I, Triana-Baltzer, G, Brum, WS, Di Molfetta, G et al.. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology. EBioMedicine. 2024;102 :105046. doi: 10.1016/j.ebiom.2024.105046. PubMed PMID:38471397 PubMed Central PMC10943661.
  87. Lee, KKY, Chattopadhyaya, B, do Nascimento, ASF, Moquin, L, Rosa-Neto, P, Amilhon, B et al.. Neonatal hypoxia impairs serotonin release and cognitive functions in adult mice. Neurobiol Dis. 2024;193 :106465. doi: 10.1016/j.nbd.2024.106465. PubMed PMID:38460800 .
  88. Therriault, J, Schindler, SE, Salvadó, G, Pascoal, TA, Benedet, AL, Ashton, NJ et al.. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol. 2024;20 (4):232-244. doi: 10.1038/s41582-024-00942-2. PubMed PMID:38429551 .
  89. Chu, M, Jiang, D, Li, D, Yan, S, Liu, L, Nan, H et al.. Atrophy network mapping of clinical subtypes and main symptoms in frontotemporal dementia. Brain. 2024;147 (9):3048-3058. doi: 10.1093/brain/awae067. PubMed PMID:38426222PubMed Central PMC11370799.
  90. Soares, C, Da Ros, LU, Machado, LS, Rocha, A, Lazzarotto, G, Carello-Collar, G et al.. The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis. Mol Psychiatry. 2024;29 (7):2261-2273. doi: 10.1038/s41380-024-02473-0. PubMed PMID:38366114 .
  91. Ferrari-Souza, JP, Brum, WS, Hauschild, LA, Da Ros, LU, Ferreira, PCL, Bellaver, B et al.. Vascular risk burden is a key player in the early progression of Alzheimer’s disease. Neurobiol Aging. 2024;136 :88-98. doi: 10.1016/j.neurobiolaging.2023.12.008. PubMed PMID:38335912 PubMed Central PMC11416150.
  92. De Bastiani, MA, Bellaver, B, Carello-Collar, G, Zimmermann, M, Kunach, P, Lima-Filho, RAS et al.. Cross-species comparative hippocampal transcriptomics in Alzheimer’s disease. iScience. 2024;27 (1):108671. doi: 10.1016/j.isci.2023.108671. PubMed PMID:38292167 PubMed Central PMC10824791.
  93. Linnemann, C, Wilke, C, Mengel, D, Zetterberg, H, Heller, C, Kuhle, J et al.. NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study. J Neurol Neurosurg Psychiatry. 2024;95 (9):822-828. doi: 10.1136/jnnp-2023-332464. PubMed PMID:38253362 PubMed Central PMC11347244.
  94. Ashton, NJ, Brum, WS, Di Molfetta, G, Benedet, AL, Arslan, B, Jonaitis, E et al.. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81 (3):255-263. doi: 10.1001/jamaneurol.2023.5319. PubMed PMID:38252443 PubMed Central PMC10804282.
  95. Scala, SG, Kang, MS, Cox, SML, Rosa-Neto, P, Massarweh, G, Leyton, M et al.. Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation. Addict Biol. 2024;29 (1):e13358. doi: 10.1111/adb.13358. PubMed PMID:38221806 PubMed Central PMC10898841.
  96. Benussi, A, Premi, E, Grassi, M, Alberici, A, Cantoni, V, Gazzina, S et al.. Diagnostic accuracy of research criteria for prodromal frontotemporal dementia. Alzheimers Res Ther. 2024;16 (1):10. doi: 10.1186/s13195-024-01383-1. PubMed PMID:38216961 PubMed Central PMC10785469.
  97. Therriault, J, Woo, MS, Salvadó, G, Gobom, J, Karikari, TK, Janelidze, S et al.. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology. Mol Neurodegener. 2024;19 (1):2. doi: 10.1186/s13024-023-00689-2. PubMed PMID:38185677 PubMed Central PMC10773025.
  98. Lantero-Rodriguez, J, Montoliu-Gaya, L, Benedet, AL, Vrillon, A, Dumurgier, J, Cognat, E et al.. CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease. Acta Neuropathol. 2024;147 (1):12. doi: 10.1007/s00401-023-02659-w. PubMed PMID:38184490 PubMed Central PMC10771353.
  99. Li, X, Naveed Iqbal Qureshi, M, Laplante, DP, Elgbeili, G, Paquin, V, Lee Jones, S et al.. Decreased amygdala-sensorimotor connectivity mediates the association between prenatal stress and broad autism phenotype in young adults: Project Ice Storm. Stress. 2024;27 (1):2293698. doi: 10.1080/10253890.2023.2293698. PubMed PMID:38131654 .
  100. Aumont, E, Bussy, A, Bedard, MA, Bezgin, G, Therriault, J, Savard, M et al.. Hippocampal subfield associations with memory depend on stimulus modality and retrieval mode. Brain Commun. 2023;5 (6):fcad309. doi: 10.1093/braincomms/fcad309. PubMed PMID:38035364 PubMed Central PMC10681971.

Search PubMed